1. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21(2): 167–178.
2. Roosen A, Chapple CR, Dmochowski RR et al. A Refocus on the Bladder as the Originator of Storage Lower Urinary Tract Symptoms: A Systematic Review of the Latest Literature. Eur Urol 2009; Aug 4.
3. Griffiths D. Imaging bladder sensations. Neurourol Urodyn 2007; 26(6 Suppl): 899–903.
4. Chapple CR, Khullar V, Gabriel Z et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008; 54(3): 543–562.
5. Landis JR, Kaplan S, Swift S et al. Efficacy of antimuscarinic therapy for overactive bladder with varying degrees of incontinence severity. J Urol 2004; 171(2 Pt 1): 752–756.
6. Chapple CR, Martinez-Garcia R, Selvaggi L et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005; 48(3): 464–470.
7. Jonas U, Rackley RR. Re: Chapple CR, Martinez-Garcia R, Selvaggi L, Toozs-Hobson P, Warnack W, Drogendijk T, Wright DM, Bolodeoku J. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005; 48: 464–470. Eur Urol 2006; 49(1): 187–188; author reply 188–190.
8. Schurch B, Schmid DM, Stohrer M. Treatment of neurogenic incontinence with botulinum toxin A. N Engl J Med 2000; 342(9): 665.
9. Reitz A, Stohrer M, Kramer G et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 2004; 45(4): 510–515.
10. Schurch B, de Seze M, Denys P et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 2005; 174(1): 196–200.
11. Grosse J, Kramer G, Stohrer M. Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 2005; 47(5): 653–659.
12. Wyndaele JJ, Van Dromme SA. Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity. Spinal Cord 2002; 40(11): 599–600.
13. Giannantoni A, Di Stasi SM, Stephen RL et al. Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study. J Urol 2004; 172(1): 240–243.
14. Schurch B, Stohrer M, Kramer G et al. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 2000; 164(3 Pt 1): 692–697.
15. Karsenty G, Boy S, Reitz A. Botulinum toxin-A (BTA) in the treatment of neurogenic detrusor overactivity incontinence (NDOI) - A prospective randomized trial to compare 30 vs. 10 injection sites. Presented at: 35th Annual Meeting of the International Continence Society, 2005, Montral, Canada.
16. Schmid DM, Sauermann P, Werner M et al. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol 2006; 176(1): 177–185.
17. Sahai A, Khan MS, Dasgupta P. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol 2007; 177(6): 2231–2236.
18. Brubaker L, Richter HE, Visco A et al. Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol 2008; 180(1): 217–222.
19. Finazzi-Agro E, Rocchi C, Pachatz C et al. Percutaneous tibial nerve stimulation produces effects on brain activity: study on the modifications of the long latency somatosensory evoked potentials. Neurourol Urodyn 2009; 28(4): 320–324.
20. Blok BF, Groen J, Bosch JL et al. Different brain effects during chronic and acute sacral neuromodulation in urge incontinent patients with implanted neurostimulators. BJU Int 2006; 98(6): 1238–1243.
21. Schmidt RA, Jonas U, Oleson KA et al. Sacral nerve stimulation for treatment of refractory urinary urge incontinence. Sacral Nerve Stimulation Study Group. J Urol 1999; 162(2): 352–357.
22. Siegel SW, Catanzaro F, Dijkema HE et al. Long-term results of a multicenter study on sacral nerve stimulation for treatment of urinary urge incontinence, urgency-frequency, and retention. Urology 2000; 56(6 Suppl 1): 87–91.
23. van Kerrebroeck PE, van Voskuilen AC, Heesakkers JP et al. Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. J Urol 2007; 178(5): 2029–2034.
24. Brubaker L, Benson JT, Bent A et al. Transvaginal electrical stimulation for female urinary incontinence. Am J Obstet Gynecol 1997; 177(3): 536–540.
25. Smith JJ 3rd. Intravaginal stimulation randomized trial. J Urol 1996; 155(1): 127–130.
26. Sand PK. Pelvic floor stimulation in the treatment of mixed incontinence complicated by a low-pressure urethra. Obstet Gynecol 1996; 88(5): 757–760.
27. Govier FE, Litwiller S, Nitti V et al. Percutaneous afferent neuromodulation for the refractory overactive bladder: results of a multicenter study. J Urol 2001; 165(4): 1193–1198.
28. van Balken MR, Vandoninck V, Gisolf KW et al. Posterior tibial nerve stimulation as neuromodulative treatment of lower urinary tract dysfunction. J Urol 2001; 166(3): 914–918.
29. Peters KM, Macdiarmid SA, Wooldridge LS et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. J Urol 2009; 182(3): 1055–1061.
30. van der Pal F, van Balken MR, Heesakkers JP et al. Percutaneous tibial nerve stimulation in the treatment of refractory overactive bladder syndrome: is maintenance treatment necessary? BJU Int 2006; 97(3): 547–550.
31. Walsh IK, Johnston RS, Keane PF. Transcutaneous sacral neurostimulation for irritative voiding dysfunction. Eur Urol 1999; 35(3): 192–196.
32. Hasan ST, Robson WA, Pridie AK et al. Transcutaneous electrical nerve stimulation and temporary S3 neuromodulation in idiopathic detrusor instability.J Urol 1996; 155(6): 2005–2011.
33. O'Dell KK, McGee S. Acupuncture for urinary urgency in women over 50: what is the evidence? Urol Nurs 2006; 26(1): 23–30.
34. Wang AC, Wang YY, Chen MC. Single-blind, randomized trial of pelvic floor muscle training, biofeedback-assisted pelvic floor muscle training, and electrical stimulation in the management of overactive bladder. Urology 2004; 63(1): 61–66.
35. Nygaard IE, Kreder KJ, Lepic MM et al. Efficacy of pelvic floor muscle exercises in women with stress, urge, and mixed urinary incontinence. Am J Obstet Gynecol 1996; 174(1 Pt 1): 120–125.
36. Burgio KL, Locher JL, Goode PS et al. Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial. JAMA 1998; 280(23): 1995–2000.
37. Bendana EE, Belarmino JM, Dinh JH et al. Efficacy of transvaginal biofeedback and electrical stimulation in women with urinary urgency and frequency and associated pelvic floor muscle spasm. Urol Nurs 2009; 29(3): 171–176.
38. Arruda RM, Castro RA, Sousa GC et al. Prospective randomized comparison of oxybutynin, functio-nal electrostimulation, and pelvic floor training for treatment of detrusor overactivity in women. Int Urogynecol J Pelvic Floor Dysfunct 2008; 19(8): 1055–1061.
39. Shafik A, Shafik IA. Overactive bladder inhibition in response to pelvic floor muscle exercises. World J Urol 2003; 20(6): 374–377.
40. Oyama IA, Rejba A, Lukban JC et al. Modified Thiele massage as therapeutic intervention for female patients with interstitial cystitis and high-tone pelvic floor dysfunction. Urology 2004; 64(5): 862–865.
41. Weiss JM. Pelvic floor myofascial trigger points: manual therapy for interstitial cystitis and the urgency-frequency syndrome. J Urol 2001; 166(6): 2226–2231.
42. Liu HT, Chancellor MB, Kuo HC. Urinary nerve growth factor level could be a biomarker in the differential diagnosis of mixed urinary inconti-nence in women. BJU Int 2008; 102(10): 1440–1444.
43. Liu HT, Chancellor MB, Kuo HC. Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder. BJU Int 2009; 103(12): 1668–1672.
44. Liu HT, Kuo HC. Urinary nerve growth factor levels are increased in patients with bladder outlet obstruction with overactive bladder symptoms and reduced after successful medical treatment. Urology 2008; 72(1): 104–108; discussion 108.
45. Kim JC, Park EY, Hong SH et al. Changes of urinary nerve growth factor and prostaglandins in male patients with overactive bladder symptom. Int J Urol 2005; 12(10): 875–880.
46. Kim JC, Park EY, Seo SI et al. Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder. J Urol 2006; 175(5): 1773–1776; discussion 1776.
47. Andersson KE, Chapple CR, Cardozo L et al. Pharmacological treatment of overactive blad-der: report from the International Consultation on Incontinence. Curr Opin Urol 2009; 19(4): 380–394.
48. Allen-Brady K, Norton PA, Farnham JM et al. Significant linkage evidence for a predisposition gene for pelvic floor disorders on chromosome 9q21. Am J Hum Genet 2009; 84(5): 678–682.
49. Chuang YC, Tyagi P, Huang CC et al. Urodynamic and immunohistochemical evaluation of intravesical botulinum toxin A delivery using liposomes. J Urol 2009; 182(2): 786–792.
50. Fang JY, Huang ZR. Intravesical drug delivery into the bladder to treat cancers. Curr Drug Deliv 2009; 6(3): 227–237.